DOCSLIB.ORG

Variable in Their Efficacy? a Description of Ion Trapping

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Variable in Their Efficacy? a Description of Ion Trapping Annals of the Rheumatic Diseases 1993; 52: 241-243 241 HYPOTHESIS Why are non-steroidal anti-inflammatory drugs so variable in their efficacy? A description of ion trapping G A Ellis, D R Blake Hypothesis Non-steroidal anti-inflammatory drugs vary in Our hypothesis is that acidic non-steroidal their aqueous solubility, but most are highly anti-inflammatory drugs (NSAIDs) undergo albumin bound and will be co-distributed with ion trapping in acidotic tissue and that this this protein. Diffusion of an NSAID into the affects not only their gastrotoxicity, which is cell follows Fick's law, as it is dependent on the well known, but also their selectivity for, and concentration gradient across the plasma their efficacy in, inflammatory joint disease. membrane and the lipid/water partition Tissue acidosis may not be a feature of all coefficient of the drug molecule. chronic inflammatory disease states, but it does For weak acids, such as most NSAIDs, the occur in inflammatory joint disease and is effective concentration gradient is that of the highly variable depending on the extent of the non-ionised form, as ionised molecules are not mismatch between synovial perfusion and lipid soluble metabolic demand. This mismatch is influ- HD D- + H+ enced not only by disease activity, but also by Non-ionised Ionised joint movement, which causes transient hypoxic episodes. Interventions, such as rest The position ofthe equilibrium depends on the and drug treatment, would serve to reduce ion intrinsic ionisation constant of the molecule trapping and, therefore, NSAID efficacy (pKa) and on the pH value of the aqueous through their effects on disease activity. The phase. The influence of pH is most profound influence of these factors on pH dependent ion around the pKa value of the molecule (fig 1). trapping may contribute to the variable efficacy For acidic NSAIDs, decreasing the pH of NSAIDs between disease states, between increases the proportion of the non-ionised patients within a disease population, and form, raises the overall lipophilicity, and within a single patient over time. enhances transport across the lipid membrane. Prostaglandins have been found in increased The pKa values for several NSAIDs at 25°C amounts in many chronic inflammatory states, are given in the table. Within tissue, the actual including rheumatoid arthritis' and osteo- values will vary slightly with temperature and arthritis,2 where they contribute to the severity the ionisation potential of the environment. and persistence of inflammation. They are Where pH gradients exist across lipid derived from arachidonic acid by the action of membranes ionisable molecules are subject to cyclo-oxygenase and it is principally through ion trapping. The non-ionised form will tend the inhibition of this enzyme that NSAIDs to equilibrate across the membrane and will exert therapeutic effects.3 Despite their move down its concentration gradient into the mechanism of action NSAIDs are not high pH compartment where it will be ionised. universally effective in all chronic inflamma- tory disease states and this may be due, in part, to the pharmacokinetics of the drugs at the cellular level. 100 [ To reach their active site within inflam- matory cells NSAIDs must be distributed to the extravascular compartment. Passage across E the vascular endothelium can be either via gaps 0 between the endothelial cells or by simple 'a Inflammation them. There ._n0 50 Research Group, diffusion through are, however, . Bone and Joint restrictions and both routes can be altered by Research Unit, disease. 0 25-29 Ashfield Street, z London El 2AD, Normally the gaps between endothelial cells United Kingdom are small, allowing only limited egress of small G A Ellis solutes, but restricting loss of protein. The D R Blake presence of inflammation weakens the Correspondence to: allow Ms Ellis. endothelial barrier, and the wider gaps water and Increasing pH Accepted for publication the extravasation of hydrated 3 November 1992 molecules and proteins, including albumin.4 Figure 1 Ionisation of a weak acid. 242 Ellis, Blake pKa Values ofvarious non-steroidal anti-inflammatory reduction in prostaglandins.'0 Further down drugs (NSAIDs) the intestinal tract pH gradients may occur but, NSAID pKa Value if correctly orientated, are much smaller as the Salicylic acid 3 0 lumenal pH in these regions only varies Diflunisal 3-3 between 7 0 and 8&0. As a class the acidic Acetylsalicylic acid 3-5 Diclofenac 3-9 NSAIDs have considerable gastrotoxicity and Mefenamic acid 4-2 their reduction of endogenous prostaglandins Ibuprofen 4-4 Phenylbutazone 4-5 is a major, but not the only, factor in this Indomethacin 4-5 effect." It is interesting that the pattern of ion Oxyphenbutazone 4.7 6-Methoxy-2-naphthylacetic acid* 5-0 trapping parallels that of the gastrotoxicity Piroxicam 5-1 profile. The incidence of endoscopically *Active metabolite ofnabumetone. proved gastric ulcers in patients treated with NSAIDs is estimated to be about 20%,/12 whereas in the intestine the adverse effects of More non-ionised drug is then pulled across NSAIDs are generally limited to subclinical the membrane and this dynamic process inflammation, and radiologically demonstrable continues until equilibrium is achieved (fig 2). ulceration and strictures occur only Ion trapping of NSAIDs within cells occasionally. '3 therefore occurs in situations where the pH of McCormack and Brune" considered the the extracellular fluid (pHe) is lower than that physicochemical characteristics of a few acidic of the intracellular fluid (pHi), such as in the NSAIDs with a lower than average gastrotoxic gastric mucosa and in acidotic diseased tissue. potential. They noted that these drugs did not Normally the pHi of a cell is about 7 1 whereas reach high concentrations in the gastric the pHe is 7 5. In vitro studies have shown, mucosa. For flufenamic acid, fenclofenac, and however, that the orientation of this pH diflunisal this was suggested to be owing to gradient is reversed when the pHe decreases their enhanced lipophilicity, whereas for below approximately 7X 1 in cells that have the azapropazone it was thought to be because it mechanisms to cope with acidification.56 is a cation at low pH values. In most situations the magnitude of the Ion trapping also occurs in tissues made measurable pHe-pHi gradient will be small, acidotic by pathophysiological mechanisms but nevertheless it can have a considerable such as in tumours and in inflammation. effect on the drug concentration at the active Research with ionisable 5-fluorouracil in rat site. In human erythrocytes in vitro, decreasing fibrosarcomas in vivo, using nuclear magnetic the pHe ofthe phosphate buffer from 7X4 to 6 8 resonance spectroscopy techniques, has shown approximately doubled the concentration of that a localised pHe reduction from 7-3 to 6-9 phenylbutazone in the intracellular compart- enhanced the cellular uptake of the drug, ment, without affecting that of the basic causing a 2-5-fold increase in the elimination compound, antipyrine.7 Physical effects can half life.'5 Such direct studies have not been enhance the pH gradient. The electrostatic conducted in inflammation. Acidic NSAIDs interaction between negatively charged groups have been shown to accumulate in inflamed in the plasma membrane reduces the pHe at tissue in several animal models, however.'6 1' the external surface of the cell. For example, In patients with joint inflammation, total with a bulk pHe of 7 0 the surface pHe is NSAID concentrations increase in the synovial calculated to be only about 6.2.8 In addition, fluid and tissue as inflammation becomes more good buffering in the unstirred layer at the severe and, therefore, more acidotic.'8 '9 surface amplifies the ion trapping effect. Although increased extravasation of albumin Replacing sodium chloride in a buffer solution bound NSAIDs will contribute to the higher with sodium citrate produced a 43-fold NSAID concentrations, ion trapping could increase in the ion trapping of salicylate.9 also have a role. The gastric mucosa has the largest pH If ion trapping does occur with NSAIDs, it gradients in the body and is the prime site for would explain why acidic NSAIDs are more NSAID trapping. These drugs accumulate in effective in vivo than NSAIDs such as the cells of this tissue and produce a prolonged proquazone and indoxole, which, although fairly potent cyclo-oxygenase inhibitors in vitro, are not acidic.20 It might also explain why more than 90% of patients with gout, with its severe synovitis, respond to NSAID treatment Low pHe Hig pH within one day, with complete resolution of / (relative) \ symptoms in five to eight days2' and why the patients with rheumatoid arthritis most likely HA HA to respond well to NSAID treatment are those with more aggressive disease.22 The acidosis of osteoarthritis is less severe and probably less persistent than in rheumatoid arthritis.23 Given H+ +±A- H+ +A- this, NSAIDs would be expected to be most effective during inflammatory and acidotic episodes and less so in the intervening periods. Differences in NSAID ion trapping may Figure 2 Ion trapping ofweak acids. pHe=pH ofthe account for some ofthe variation in therapeutic extracellularfluid; pHi=pH ofthe intracellularfluid. response within a disease group,24 as acidosis NSAIDs anid ion trapping 243 3 Vane J R. Inhibition of prostaglandin synthesis as a is a dynamic variable and is under the influence mechanism of action for aspirin-like drugs. Natirc 197 1; of diverse factors. In rheumatoid arthritis the 231: 232-5. extent of acidosis differs considerably between 4 Simkin P A, Pizzorno J E. Svnovial permeabilitv and rheumatoid arthritis. Arthritis Rlicioiii 1979; 22: 689-96. patients and seems to be compounded by 5 Nuccitelli R, Heiple J M. Summary of the evidence and movement.'9 2 2' Flexion of an inflamed joint discussion concerning the involvement of pHi in the control of cellular functions.
Load more

Recommended publications
  • Solid Solution Compositions and Use in Chronic Inflammation
    (19) *EP003578172A1* (11) EP 3 578 172 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.12.2019 Bulletin 2019/50 A61K 9/14 (2006.01) A61K 47/14 (2017.01) A61K 47/44 (2017.01) A61K 31/12 (2006.01) (2006.01) (2006.01) (21) Application number: 19188174.7 A61K 31/137 A61K 31/167 A61K 31/192 (2006.01) A61K 31/216 (2006.01) (2006.01) (2006.01) (22) Date of filing: 14.01.2014 A61K 31/357 A61K 31/366 A61K 31/4178 (2006.01) A61K 31/4184 (2006.01) A61K 31/522 (2006.01) A61K 31/616 (2006.01) A61K 31/196 (2006.01) (84) Designated Contracting States: • BREW, John AL AT BE BG CH CY CZ DE DK EE ES FI FR GB London, Greater London EC2Y 8AD (GB) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • REILEY, Richard Robert PL PT RO RS SE SI SK SM TR London, Greater London EC2Y 8AD (GB) • CAPARRÓS-WANDERLEY, Wilson (30) Priority: 14.01.2013 US 201361752356 P London, Greater London EC2Y 8AD (GB) 04.02.2013 US 201361752309 P (74) Representative: Clements, Andrew Russell Niel et (62) Document number(s) of the earlier application(s) in al accordance with Art. 76 EPC: Schlich 14702460.8 / 2 925 367 9 St Catherine’s Road Littlehampton, West Sussex BN17 5HS (GB) (71) Applicant: InFirst Healthcare Limited London EC2Y 8AD (GB) Remarks: This application was filed on 24-07-2019 as a (72) Inventors: divisional application to the application mentioned • BANNISTER, Robin Mark under INID code 62.
    [Show full text]
  • Studies in Laboratory Animals to Assess the Safety of Anti-Inflammatory Agents in Acute Porphyria
    Ann Rheum Dis: first published as 10.1136/ard.46.7.540 on 1 July 1987. Downloaded from Annals of the Rheumatic Diseases, 1987; 46, 540-542 Studies in laboratory animals to assess the safety of anti-inflammatory agents in acute porphyria KENNETH E L McCOLL, GEORGE G THOMPSON, AND MICHAEL R MOORE From the University Department of Medicine, Western Infirmary, Glasgow SUMMARY The safety of various anti-inflammatory drugs in acute porphyria was assessed by examining their effect on rat hepatic haem synthesis. Azapropazone, chloroquine, and gold increased 6-aminolaevulinic acid (ALA) synthase activity, indicating that they are liable to precipitate porphyric crises. Aspirin, ibuprofen, indomethacin, ketoprofen, flurbiprofen, phenylbutazone, naproxen, prednisolone, and penicillamine did not increase ALA synthase activity and should be safe in porphyria. Though these animal studies can be used as a guide to prescribing in patients with acute porphyria, some caution is still required as species may vary in their response to inducing agents. Key words: chloroquine, azapropazone, gold, b-aminolaevulinic acid synthase. copyright. The acute hepatic porphyrias which comprise acute controlling enzyme of haem biosynthesis 6- intermittent porphyria, hereditary coproporphyria, aminolaevulinic acid (ALA) synthase in rat hepatic and variegate porphyria are examples of pharma- tissue. To confirm the reliability of the animal cogenetic disease. They are the result of deficien- model, phenobarbitone was also tested. For each cies of individual enzymes in the pathway of haem drug examined six male Sprague-Dawley rats re- biosynthesis and are inherited in an autosomal ceived the test drug and six control rats received the dominant fashion.2 Subjects with the genetic trait appropriate placebo solution.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Drug-Induced Peptic Ulcer Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by OAR@UM risk populations only.7 The prevalence of endoscopically confirmed gastrointestinal ulcers in NSAID users is quoted to be between 15% and 30%. Between 12% to 30% of NSAID-induced ulcers are gastric ulcers, whereas 2% to 19% are duodenal ulcers. NSAID-induced ulcers are symptomatic only in 1% of patients after three to six months and in 2 to 4% of patients after one year. Inappropriately they do not correlate well with pain because the analgesic action of NSAIDs may mask the ulcer pain.2 Drug-induced peptic Understanding the method by which NSAIDs cause gastric damage has helped in the development of prophylactic agents that ulcer disease 1 red uce their toxicity. The mechanism by which NSAIDs are thought to damage the Valerie Vella B Pharm(Hons), PgDip Clin Pharm (Aberdeen) gastrointestinal tract is four-fold. Clinical Pharmacist, St Luke’s Hospital, Guardamangia, Malta a) Topical injury Email: [email protected] Originally it was thought that NSAIDs damaged the gastric epithelium by Key words: Peptic ulcer, medicines, prostaglandins, gastrointestinal protection, intracellular accumulation of these drugs in gastrointestinal toxicity an ionised state.1 However the fact that enteric-coated formulations, pro-drugs, For more than a century, peptic ulcer disease has been a rectal and parenteral administration of 1 major cause of morbidity and mortality. Peptic ulcer disease NSAIDs still resulted in gastrointestinal is a heterogeneous group of disorders involving the damage despite the apparent absence of gastrointestinal tract and results from an imbalance between direct mucosal contact implies a minor role the aggressive forces of gastric acid and pepsin and the for topical injury1,2.
    [Show full text]
  • Fatal Hepatitis Associated with Diclofenac
    Gut: first published as 10.1136/gut.27.11.1390 on 1 November 1986. Downloaded from Gut, 1986, 27, 1390-1393 Case reports Fatal hepatitis associated with diclofenac E G BREEN, J McNICHOLL, E COSGROVE, J MCCABE, AND F M STEVENS From the Department of Medicine, Regional Hospital, Galway, Eire SUMMARY Non-steroidal anti-inflammatory agents (NSAIDS) are a well recognised cause of hepatotoxicity. Diclofenac, a relatively new NSAID, was first introduced into the UK in 1979. Five cases of hepatitis have recently been reported, principally in the French literature. -5 We report the first fulminant case of hepatitis in the English literature in a patient taking diclofenac and indomethacin. Diclofenac is a member of the arylalkanoic group of 100 mg per day for five weeks. Ferrous sulphate one NSAIDS (Fig. 1). Three other agents in this group tablet daily was added on 16 May. The patient was have been shown to be significantly hepatotoxic. admitted to hospital on 26 June. A week before this Ibufenac was withdrawn from circulation because of he had felt unwell with anorexia, nausea, abdominal the frequent rise in transaminases,6 7 the use of discomfort, and dark urine. On admission he was benoxaprofen was stopped in Britain after 10 icteric, the liver edge was palpable 4 cm below the patients died with hepatitis8 9 and more recently a costal margin and there were no signs of chronic fatal case of hepatitis due to pirprofen has been liver disease. Ultrasound showed early ascites with reported."' Early reports about diclofenac showed no obstruction of the biliary tract.
    [Show full text]
  • Cross-Reactive Mechanism for the False Elevation of Free Triiodothyronine in the Patients Treated with Diclofenac
    Endocrine Journal 2001, 48 (6), 717-722 NOTE Cross-Reactive Mechanism for the False Elevation of Free Triiodothyronine in the Patients Treated with Diclofenac KEIZO KASONO, HAJIME HIKINO*, SHINJI FUJINO**, NoBUYUKI TAKEMOTO*, TosHIHIRO KAI*, KIYosHI YAMAGUCHI***, FUMio KONISHI* AND MASANOBU KAWAKAMI Department of Endocrinology and Metabolism, Jichi Medical School, Omiya Medical Center, 1-847, Amanuma-cho, Saitama 330-8503, Japan *Department of Surgery , Jichi Medical School, Omiya Medical Center, 1-847, Amanuma-cho, Saitama 330-8503, Japan **Department of Pathology , Jichi Medical School, Omiya Medical Center, 1-847, Amanuma-cho, Saitama 330-8503, Japan ***Department of Neurology , Jichi Medical School, Omiya Medical Center, 1-847, Amanuma-cho, Saitama 330-8503, Japan Abstract. We report three cases of patients exhibiting a false elevation of serum free triiodothyronine (FT3) as a result of a cross-reaction with diclofenac. The first case is a 66-yr-old woman with a long history of rheumatoid arthritis (RA). The patient was receiving diclofenac for the treatment of her RA. The patient was subsequently diagnosed as having thyroid papillary adenocarcinoma and received a subtotal thyroidectomy. After the operation, the patient exhibited postoperative hypothyroidism except for a gradual elevation of FT3. The other two patients also exhibited an elevated serum FT3 level after the administration of diclofenac. Serum FT3 levels in these pa- tients decreased to normal or below normal after diclofenac administration was discontinued. In the first case, the elimination of immunoglobulin from the sera using polyethylene glycol precipitation did not reduce the FT3 level. In our hospital, Vitros ECi (enhanced chemiluminescence enzyme immunoassay) system and Vitros FT3 kit were used for FT3 assay.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Individual Nsaids and Upper Gastrointestinal Complications a Systematic Review and Meta-Analysis of Observational Studies (The SOS Project)
    Drug Saf 2012; 35 (12): 1127-1146 SYSTEMATIC REVIEW 0114-5916/12/0012-1127 Adis ª 2012 Castellsague et al., publisher and licensee Springer International Publishing AG. This is an open access article published under the terms of the Creative Commons License ‘‘Attribution-NonCommercial-NoDerivative 3.0‘‘ (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits non-commercial use, distribution, and reproduction, provided the original work is properly cited and not altered. Individual NSAIDs and Upper Gastrointestinal Complications A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project) Jordi Castellsague,1 Nuria Riera-Guardia,1 Brian Calingaert,2 Cristina Varas-Lorenzo,1 Annie Fourrier-Reglat,3 Federica Nicotra,4 Miriam Sturkenboom5 and Susana Perez-Gutthann1, on behalf of the investigators of the Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project 1 RTI Health Solutions, Barcelona, Spain 2 RTI Health Solutions, Research Triangle Park, NC, USA 3 Universite V. Segalen, Bordeaux, France 4 University Milan-Bicocca, Milan, Italy 5 Erasmus University Medical Center, Rotterdam, the Netherlands Abstract Background: The risk of upper gastrointestinal (GI) complications associated with the use of NSAIDs is a serious public health concern. The risk varies between individual NSAIDs; however, there is little information on the risk associated with some NSAIDs and on the impact of risk factors. These data are necessary to evaluate the benefit-risk of individual NSAIDs for clinical and health policy decision making. Within the European Community’s Seventh Framework Programme, the Safety Of non-Steroidal anti-inflammatory drugs (NSAIDs) [SOS] project aims to develop decision models for regulatory and clinical use of individual NSAIDs according to their GI and cardiovascular safety.
    [Show full text]
  • Long-Term Use of Anti-Inflammatory Drugs and Risk of Atrial Fibrillation
    ORIGINAL INVESTIGATION Long-term Use of Anti-inflammatory Drugs and Risk of Atrial Fibrillation Raffaele De Caterina, MD, PhD; Ana Ruigo´mez, MD, PhD; Luı´s Alberto Garcı´a Rodrı´guez, MD, MSc Background: Previous reports have described an asso- ratio [RR], 2.49; 95% confidence interval [CI], 1.56- ciation between the use of corticosteroids (steroidal anti- 3.97). However, we also found that the current use of inflammatory drugs [SAIDs]) and the risk of atrial fibril- NSAIDs was associated with an increased risk of chronic lation (AF). We sought to determine the existence of a AF (RR, 1.44; 95% CI, 1.08-1.91). Such risk was further similar association for non-SAIDs (NSAIDs). increased among long-term users with a treatment du- ration of longer than 1 year (RR, 1.80; 95% CI, 1.20- Methods: We identified patients aged 40 to 89 years with 2.72). The increased risk of chronic AF was not ex- a first-ever diagnosis of AF in 1996 in a United King- plained by the occurrence of heart failure. The use of dom primary care database and classified them as hav- NSAIDs was not associated with paroxysmal AF. ing paroxysmal or chronic AF. After validation with their primary care physicians, 1035 patients were confirmed Conclusions: The use of NSAIDs, as for SAIDs, is asso- as having incident chronic AF and 525 as having parox- ciated with an increased risk of chronic AF. Because the ysmal AF. Two separate nested case-control analyses es- use of anti-inflammatory drugs in general is a marker for timated the risk of first-time chronic and paroxysmal AF underlying inflammatory disorders, inflammation may among users of SAIDs and NSAIDs.
    [Show full text]
  • Søgeprotokol for Nationale Kliniske Retningslinjer
    Søgeprotokol for nationale kliniske retningslinjer Projekttitel/aspekt NKR behandling af patienter med lumbal spinalstenose – Søgning efter primærlitteratur Fagkonsulent /projektleder Rikke Rousing / Maria Herlev Ahrenfeldt Søgespecialist Kirsten Birkefoss Senest opdateret 23.12.2016 Fokuserede spørgsmål Bør patienter med lumbal spinalstenose have tilbudt aktiv PICO 1: behandling i form af superviseret træning fremfor vanlig behandling? PICO 2: Bør patienter med lumbal spinalstenose have tilbudt ledmobiliserende behandling frem for vanlig behandling? PICO 3: Bør patienter med lumbal spinalstenose have tilbudt paracetamol frem for ingen smertestillende behandling? PICO 4: Bør patienter med lumbal spinalstenose have tilbudt non steroid antiinflammatorisk medicin (NSAID) frem for ingen smertestillende behandling? PICO 5: Bør patienter med lumbal spinalstenose have tilbudt smertestillende medicin i form af opioider i tillæg til eventuel behandling med svage smertestillende? PICO 6: Bør patienter med lumbal spinalstenose have tilbudt muskelrelaxantia i tillæg til eventuel behandling med svage smertestillende? PICO 7: Bør patienter med lumbaspinalstenose have tilbudt medicin for neuropatiske smerter? PICO 8: Bør patienter med lumbal spinalstenose have tilbudt kirurgisk dekompression i tilfælde af manglende effekt af ikke kirurgisk behandling? PICO 9: Bør patienter med lumbal spinalstenose have tilbudt stivgørende operation med eller uden instrumentering i tillæg til dekompression? PICO 10: Bør patienter opereret for lumbal spinalstenose tilbydes
    [Show full text]
  • Non Steroidal Anti-Inflammatory Drugs
    Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney.
    [Show full text]
  • The Acceleration of Articular Cartilage Degeneration in Osteoarthritis by Nonsteroidal Anti-Inflammatory Drugs Ross A
    WONDER WHY? THE ACCELERATION OF ARTICULAR CARTILAGE DEGENERATION IN OSTEOARTHRITIS WONDER WHY? The Acceleration of Articular Cartilage Degeneration in Osteoarthritis by Nonsteroidal Anti-inflammatory Drugs Ross A. Hauser, MD A B STRA C T introduction over the past forty years is one of the main causes of the rapid rise in the need for hip and knee Nonsteroidal anti-inflammatory drugs (NSAIDs) are replacements, both now and in the future. among the most commonly used drugs in the world for the treatment of osteoarthritis (OA) symptoms, and are While it is admirable for the various consensus and taken by 20-30% of elderly people in developed countries. rheumatology organizations to educate doctors and Because of the potential for significant side effects of the lay public about the necessity to limit NSAID use in these medications on the liver, stomach, gastrointestinal OA, the author recommends that the following warning tract and heart, including death, treatment guidelines label be on each NSAID bottle: advise against their long term use to treat OA. One of the best documented but lesser known long-term side effects The use of this nonsteroidal anti-inflammatory of NSAIDs is their negative impact on articular cartilage. medication has been shown in scientific studies to accelerate the articular cartilage breakdown In the normal joint, there is a balance between the in osteoarthritis. Use of this product poses a continuous process of cartilage matrix degradation and significant risk in accelerating osteoarthritis joint repair. In OA, there is a disruption of the homeostatic breakdown. Anyone using this product for the pain state and the catabolic (breakdown) processes of of osteoarthritis should be under a doctor’s care and chondrocytes.
    [Show full text]